Reuters - While the market for initial public offerings has shut down in all industries, with no deals in the United States in nearly three months, biotechnology companies desperate for capital will likely be waiting in line far longer than others when it does re-open.
This entry was posted
on Friday, October 31st, 2008 at 5:56 pm and is filed under Market News.
You can follow any responses to this entry through the RSS 2.0 feed.
Both comments and pings are currently closed.
